Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective observational study of MicroNet covered stent implantation in the elevated risk peripheral lesions (high lesion load, thrombus containing, highly calcified).
Open-label, non randomized, single arm observational study. Jagiellonian University Medical College research project.
Peripheral artery stents in routine use (both balloon expandable and self-expendable) do not sufficiently prevent distal embolization. They might induce a "cheese-grater" effect - a consequence of their single layer design with uncovered space between stent struts.
Aim of the study is to evaluate short and long term safety and efficacy of MicroNet covered stent implantation in the high risk lesions beyond the carotid bifurcation. Treatment eligibility will be evaluated by a Vascular Team process (angiologist, vascular surgeon, cardiologist). Optimal pharmacotherapy will be administered according to the current guidelines.
Symptomatic and asymptomatic patients with peripheral artery disease requiring endovascular treatment for high risk stenosis (soft plaque, highly calcific plaque) per Vascular Team assessment.
A group of 30-50 consecutive patients meeting inclusion and exclusion criteria will be enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MicroNet covered stenting (interventional) | MicroNet covered stent implantation for increased risk arterial lesions beyond the carotid bifurcation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation | Device | Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of procedural success | Procedural success, defined as technical success (successful delivery and implantation of the stent) AND residual stenosis ≤ 30% of vessel lumen diameter AND clinical success (no peri-procedural complications) | Up to 48 hours after procedure or until hospital discharge, whichever came first. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of In-hospital MACNE (Major Adverse Cardiovascular or Neurological Events) | In-hospital MACNE (death, stroke, myocardial infarction, acute limb or target organ ischemia) | Up to 48 hours after procedure or until hospital discharge, whichever came first. |
| Number of MACNE at 30 days |
Not provided
General
Inclusion Criteria:
Exclusion Criteria:
Angiographic
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with peripheral artery stenosis evaluated by Vascular Team with endovascular treatment recommendation and high risk morphology plaque
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Piotr Musialek, MD, DPhil | Contact | +48126142287 | p.musialek@szpitaljp2.krakow.pl |
| Name | Affiliation | Role |
|---|---|---|
| Piotr Musialek, MD, DPhil | John Paul II Hospital, Krakow | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Cardiac and Vascular Diseases, The John Paul II Hospital | Recruiting | Krakow | Maloplska | 31-202 | Poland |
Not provided
| ID | Term |
|---|---|
| D016491 | Peripheral Vascular Diseases |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
MACNE at 30 days (death, stroke, myocardial infarction, acute limb or target organ ischemia) |
| At 30 days after procedure |
| Number of MACNE at 6 months | MACNE at 6 months (death, stroke, myocardial infarction, acute limb or target organ ischemia) | At 6 months after procedure |
| Rate of peri-procedural complications | Any peri-procedural complications until 48 hrs | Up to 48 hours after procedure |
| Duplex Ultrasound Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in the stented segment at discharge | Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) on ultrasound evaluation of the stented segment (if accessible) | 24 hours after procedure |
| Duplex Ultrasound Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in the stented segment at 6 months | Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) on ultrasound evaluation of the stented segment (if accessible) | At 6 months after procedure |
| Duplex Ultrasound Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel at 12 months | Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) on ultrasound evaluation of the stented segment (if accessible) | At 12 months after procedure |
| Vessel patency in CT angiography at 6 months | Vessel patency in CT angiography (if not contraindicated) at 6 months | At 6 months after procedure |